Bambusa Therapeutics, Inc. (BBTX)
| Market Cap | 779.93M |
| Revenue (ttm) | n/a |
| Net Income | -48.70M |
| EPS | -6.08 |
| Shares Out | 50.94M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 286,943 |
| Open | 16.20 |
| Previous Close | 16.07 |
| Day's Range | 15.31 - 16.75 |
| 52-Week Range | 13.60 - 17.42 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About BBTX
Bambusa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops long-acting bispecific antibodies for the treatment of immunological and inflammatory disorders. The company develops BBT001 for Type 2 inflammatory dermatological conditions, including atopic dermatitis, chronic spontaneous urticaria, and prurigo nodularis. It also develops BBT002, a long-acting bispecific antibody for respiratory and other Type 2 inflammatory diseases. Additionally, the company develops BBT003, a long-acting bispecific antibody for inflammatory b... [Read more]
Financial Performance
Financial StatementsNews
Opening Day: Aspen, Bambusa Therapeutics make market debuts
The biotech IPO market continued to see activity last week, with Aspen Neuroscience and Bambusa Therapeutics making their public market debuts as investors showed continued interest in early-stage hea...
Bambusa Therapeutics Announces Pricing of Upsized Initial Public Offering
BOSTON, Oct. 29, 2026 /PRNewswire/ -- Bambusa Therapeutics, Inc. (Nasdaq: BBTX) ("Bambusa Therapeutics" or "Bambusa"), a clinical-stage biopharmaceutical company developing next-generation, long-actin...
Bambusa Therapeutics Registration statement: Registration filing
Bambusa Therapeutics filed a registration statement on October 26, 2026, providing details about a securities offering with the SEC.
Parkinsons-focused Aspen and bispecific biotech Bambusa plan IPOs
Parkinsons disease cell therapy-focused Aspen Neuroscience and bispecific biotech
Immunology and inflammation biotech Bambusa Therapeutics files for a $100 million IPO
Bambusa Therapeutics, a Phase 2 biotech developing bispecific antibodies for inflammatory diseases, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
Bambusa Therapeutics IPO Registration Document (S-1)
Bambusa Therapeutics has filed to go public with an IPO on the NASDAQ
Bambusa Therapeutics Registration statement: Registration filing
Bambusa Therapeutics filed a registration statement on October 9, 2026, providing details about a securities offering with the SEC.